Tesamorelin + Ipamorelin Overview
Tesamorelin + Ipamorelin is a dual-action peptide combination designed to stimulate the body’s growth-hormone pathway from two complementary directions. Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analogue, while Ipamorelin is a selective growth hormone secretagogue that acts through the ghrelin receptor.
The combination has become particularly popular in the peptide space because it brings together GHRH and ghrelin-receptor signaling, creating a broader approach to stimulating growth hormone release than either peptide alone.
Tesamorelin also has considerably stronger human evidence than Ipamorelin and is FDA-approved for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Ipamorelin, meanwhile, remains an unapproved peptide. Importantly, the combination itself has not been evaluated in a dedicated human clinical trial, so claims about the blend should not be confused with evidence for tesamorelin alone.
Product Information
Tesamorelin works primarily by mimicking GHRH and stimulating the pituitary gland to release growth hormone. Ipamorelin works through the GHS-R1a/ghrelin receptor, providing another route for stimulating GH secretion.
This complementary mechanism is the main reason the two peptides are commonly paired. Research on GHRH and ghrelin/GH-secretagogue pathways has demonstrated that activating both pathways can produce stronger GH responses than either pathway alone.
How Does Tesamorelin + Ipamorelin Work?
In simple terms, Tesamorelin provides the GHRH signal while Ipamorelin provides the secretagogue signal. Together, they stimulate the body’s natural GH-release pathway through two different receptors.
Potential Benefits
Supports Growth Hormone Release
Tesamorelin and Ipamorelin are both designed around stimulating growth hormone secretion, making this combination particularly attractive to people interested in GH-related pathways. Tesamorelin has demonstrated significant GH and IGF-1 effects in clinical studies, while Ipamorelin has been shown to stimulate GH release in human pharmacological studies.
Supports Body Composition
Tesamorelin has attracted considerable attention for its effects on visceral abdominal fat, with clinical trials demonstrating reductions in visceral adipose tissue in its approved population. Adding Ipamorelin creates a combination that is particularly appealing to people interested in body composition and metabolic pathways.
Supports Muscle Recovery & Lean Tissue
Growth hormone and IGF-1 are closely involved in tissue growth, protein metabolism, and recovery processes. For this reason, Tesamorelin + Ipamorelin is widely sought after in performance and recovery circles where maintaining lean tissue and supporting physical recovery are major priorities.
Supports Recovery & Physical Performance
The GH pathway plays an important role in tissue repair and recovery following physical stress. By stimulating this pathway, the combination has become popular among people looking for a peptide stack centered around recovery, body composition, and physical performance.
Two-Pathway GH Support
The biggest attraction of the combination is its complementary mechanism. Tesamorelin activates the GHRH pathway while Ipamorelin activates the ghrelin/GHS-R1a pathway, giving the formulation a broader GH-secretagogue profile than using either peptide independently.
Side Effects
Because both peptides influence the growth-hormone/IGF-1 axis, possible effects can include water retention, swelling, joint discomfort, headache, numbness or tingling, injection-site reactions, and changes in glucose regulation. Elevated IGF-1 is also a known consideration with GH-pathway therapies.
Dosage
Online peptide protocols commonly describe Tesamorelin + Ipamorelin combinations in the range of approximately 0.25–2 mg of Tesamorelin with 0.125–1 mg of Ipamorelin per day, generally using gradual increases rather than starting at the upper end. A commonly referenced 5 mg + 5 mg blend protocol, for example, progresses from approximately 250 mcg Tesamorelin + 125 mcg Ipamorelin initially toward 2 mg + 1 mg daily.
Other peptide-protocol sources commonly describe approximately 1–2 mg Tesamorelin once daily alongside 200–300 mcg Ipamorelin, usually administered subcutaneously. These figures represent commonly published peptide-community protocols rather than an FDA-approved dosage for the combination.
Where to Buy Tesamorelin + Ipamorelin?
Purerawz does not sell Tesamorelin + Ipamorelin or any other peptide products. Purerawz is an affiliate marketing and informational website. Readers can use the affiliate links provided on the website to find independent suppliers and review their available formulations.
References
Lallès JP, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Clin Pharmacokinet. 1999. PMID: 10496658. PubMed reference
Purerawz Disclaimer
Purerawz does not sell, manufacture, stock, dispense, or directly supply any of the products discussed on this website. Purerawz is an independent information and affiliate platform. Where available, links may direct readers to independent third-party providers, and Purerawz may receive a commission from qualifying purchases at no additional cost to the reader.
The information provided is for educational and informational purposes only. Dosage figures may reflect published research protocols, historical clinical use, or reported community practices and should not be interpreted as personalized medical instructions. Research findings—particularly those from animal, cellular, or small early-stage studies—do not establish that a product is safe or effective for every individual or condition.
